2026 Interim report
Filed with HKEX · Stock code 6978 · · 64 pages · English
Corporate Information Financial and Operational Data Highlights Corporate Profile Management Discussion and Analysis Other Information 2 4 5 6 21 Condensed Consolidated Statement of Profit or Loss 36 and Other Comprehensive Income Condensed Consolidated Statement of Financial Position 37 Condensed Consolidated Statement of Changes in Equity 39 Condensed Consolidated Statement of Cash Flows 40 Note
Immunotech Biopharm Ltd on 6ix
Earlier from Immunotech Biopharm
- Major transaction further delay in despatch of circular in relation to the construction of the new biological drug R&D and industrialisation based in beijing
- Change of senior management
- Immunotech Biopharm: Major transaction construction agreement in relation to the construction of the new biological drug R&D and industrialisation base in beijing
- Voluntary announcement establishment of and investment in cellular immunotherapy specialised industry fund as a limited partner
Later from Immunotech Biopharm
- Supplemental announcement to the annual report for the year ended 31 December 2025
- Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 September 2026
Follow Immunotech Biopharm into a list and get an email when it puts out news.
Follow Immunotech Biopharm